Conceivable Life Sciences has secured $50 million in Series A funding to accelerate the development and commercialisation of the world’s first AI-powered automated IVF laboratory. This revolutionary technology introduces robotic precision and AI algorithmic exactitude to the IVF process, standardising the over 200 intricate steps involved with the goal of consistently successful IVF outcomes. The funding will support the company’s mission to make IVF more accessible, scalable, and effective. The technology addresses the core challenges facing fertility clinics today, including inconsistent success rates, capacity constraints, and accessibility barriers. The company is currently conducting a 100-patient pilot study with early indications suggesting robotic precision and AI-driven protocols outperform traditional manual approaches.